Hepatitis C Virus-Related One-Year Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial

ConclusionDirect-acting antiviral usage after complete hepatocellular carcinoma ablation significantly decreases the 1-year HCC recurrence rates, but the risk of recurrence is still not eliminated.  The study registration number onclinicaltrials.gov: NCT04653818 (initial release on 28/11/2020).
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research